Effects of remimazolam on hemodynamics in patients undergoing fiberoptic bronchoscopy after cardiovascular surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200056799

Enrollment

Unknown

Registered

2022-02-17

Start date

2022-03-01

Completion date

Unknown

Last updated

2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fiberoptic bronchoscope

Interventions

Remazolam group:Sedation with remazolam

Propofol group:Sedation with propofol

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age = 18 years; 2.After cardiovascular surgery; 3.Fiberoptic bronchoscopy is planned; 4.ASA grade?-?; 5.Sign informed consent.

Exclusion criteria

Exclusion criteria: 1.During pregnancy or lactation; 2. History of allergic reaction to sedative drugs; 3. Suffering from mental system diseases (severe depression, schizophrenia, mania, bipolar disorder, insanity, etc.), long-term history of taking psychotropic drugs and cognitive impairment; 4. Myasthenia gravis patients; 5. Severe hypoxemia, SPO2 160 mmHg and / or diastolic blood pressure > 100 mmHg, MAP< 55 mmHg and heart rate < 50 bpm/ min under the control of vasoactive drugs; 7. Uncontrollable arrhythmia; 8. Severe coagulation disorder; 9.Patients in deep coma, RASS score - 5.

Design outcomes

Primary

Measure	Time frame
heart rate;mean arterial pressure;hemodynamic parameters measured by non-invasive hemodynamic monitor (CI, SVRI, TFC, SVV, STR);incidence of hypotension;	—

Countries

China

Contacts

Public ContactZeng Xiaochun

sunnyblue926@126.com0771-5605916

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026